A Multimodal Nomogram Predicting the Risk of Cognitive Impairment in Parkinson Disease.
- 1Parkinson and Movement Disorder Center, Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA.
Abstract
Background
Cognitive impairment is the most consequential non-motor complication of Parkinson's disease (PD), yet no validated tool integrates multimodal data to predict individualized risk trajectories.Objectives
The aim is to develop and internally validate a time-to-event nomogram for predicting 5-year risk of cognitive impairment in PD using the Parkinson's Precision Markers Initiative (PPMI).Methods
We analyzed 1188 PD patients with normal cognition at their first cognitive assessment and up to 13 years of follow-up. Twenty-seven candidate predictors across seven domains were evaluated. Least absolute shrinkage and selection operator (LASSO)-penalized Cox regression performed variable selection. Performance was assessed via nested cross-validation, bootstrap optimism correction, calibration, and time-dependent area under the curve (AUC).Results
During median follow-up of 3.0 years (interquartile range [IQR], 2.0-5.0), 457 patients (38.5%) developed cognitive impairment. LASSO selected 14 predictors. The Cox model achieved a concordance index (C-index) of 0.747 (optimism-corrected: 0.733; nested CV: 0.736 ± 0.042), with apparent time-dependent AUC of 0.77, 0.79, and 0.83 at 3, 5, and 8 years (held-out: 0.75, 0.78, and 0.81). A companion model without genetic predictors, for unknown GBA status, performed similarly (optimism-corrected C-index, 0.729). The strongest predictors were age (hazard ratio [HR], 1.05/year; P < 0.001), GBA mutation (HR, 2.05; P < 0.001), cognitive complaints (HR, 1.67; P < 0.001), and Symbol Digit Modalities Test (HR, 0.98/point; P = 0.001).Conclusions
A multimodal nomogram integrating clinical, cognitive, genetic, and neuropsychiatric predictors provides individualized estimates of 5-year risk of cognitive impairment in PD; after external validation, it may support prognostic counseling and trial enrichment.
Related
- Systematic Modality Ablation of Multimodal Machine Learning for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer's Disease
- Prediction of cognitive impairment in Parkinson’s disease using TabPFN: an integrative analysis of clinical data, longitudinal trajectories, and lipidomics
- Enhancing deep sleep with auditory stimulation to boost cognitive training responsiveness in people with Parkinson's disease and mild cognitive impairment: Rationale and design of the double-blind randomized controlled trial PD-CogT-Sleep
- Multimodal neuroimaging and electrophysiological signatures in amnestic mild cognitive impairment with different amyloid-β deposition status: correlations with cognitive function and diagnostic value
- Plasma ceramide ratios define metabolic–inflammatory associations with cognitive impairment in Parkinson’s disease
BibTeX
@article{negida2026multimodal,
title = {{A Multimodal Nomogram Predicting the Risk of Cognitive Impairment in Parkinson Disease.}},
author = {Ahmed Negida},
journal = {Movement disorders clinical practice},
year = {2026},
month = nov,
doi = {10.1002/mdc3.70884},
url = {https://europepmc.org/article/MED/42972958},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - A Multimodal Nomogram Predicting the Risk of Cognitive Impairment in Parkinson Disease.
AU - Ahmed Negida
PY - 2026
DA - 2026/11/02
JO - Movement disorders clinical practice
DO - 10.1002/mdc3.70884
UR - https://europepmc.org/article/MED/42972958
AB - Background Cognitive impairment is the most consequential non-motor complication of Parkinson's disease (PD), yet no validated tool integrates multimodal data to predict individualized risk trajectories.Objectives The aim is to develop and internally validate a time-to-event nomogram for predicting 5-year risk of cognitive impairment in PD using the Parkinson's Precision Markers Initiative (PPMI).Methods We analyzed 1188 PD patients with normal cognition at their first cognitive assessment and up to 13 years of follow-up. Twenty-seven candidate predictors across seven domains were evaluated. Least absolute shrinkage and selection operator (LASSO)-penalized Cox regression performed variable selection. Performance was assessed via nested cross-validation, bootstrap optimism correction, calibration, and time-dependent area under the curve (AUC).Results During median follow-up of 3.0 years (interquartile range [IQR], 2.0-5.0), 457 patients (38.5%) developed cognitive impairment. LASSO selected 14 predictors. The Cox model achieved a concordance index (C-index) of 0.747 (optimism-corrected: 0.733; nested CV: 0.736 ± 0.042), with apparent time-dependent AUC of 0.77, 0.79, and 0.83 at 3, 5, and 8 years (held-out: 0.75, 0.78, and 0.81). A companion model without genetic predictors, for unknown GBA status, performed similarly (optimism-corrected C-index, 0.729). The strongest predictors were age (hazard ratio [HR], 1.05/year; P < 0.001), GBA mutation (HR, 2.05; P < 0.001), cognitive complaints (HR, 1.67; P < 0.001), and Symbol Digit Modalities Test (HR, 0.98/point; P = 0.001).Conclusions A multimodal nomogram integrating clinical, cognitive, genetic, and neuropsychiatric predictors provides individualized estimates of 5-year risk of cognitive impairment in PD; after external validation, it may support prognostic counseling and trial enrichment.
SN - 2330-1619
ER -